Cargando…
Biomedical Prevention: State of the Science
Preexposure prophylaxis (PrEP) and treatment as prevention (TasP) involve the use of antiretroviral (ARV) drugs by human immunodeficiency virus (HIV)-negative and -positive individuals to reduce HIV acquisition and transmission, respectively. Clinical science has delivered a consistently high effect...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060254/ https://www.ncbi.nlm.nih.gov/pubmed/24926033 http://dx.doi.org/10.1093/cid/ciu297 |
_version_ | 1782321346635628544 |
---|---|
author | McCormack, Sheena M. Gafos, Mitzy Desai, Monica Cohen, Myron S. |
author_facet | McCormack, Sheena M. Gafos, Mitzy Desai, Monica Cohen, Myron S. |
author_sort | McCormack, Sheena M. |
collection | PubMed |
description | Preexposure prophylaxis (PrEP) and treatment as prevention (TasP) involve the use of antiretroviral (ARV) drugs by human immunodeficiency virus (HIV)-negative and -positive individuals to reduce HIV acquisition and transmission, respectively. Clinical science has delivered a consistently high effect size for TasP and a range from 0%–73% reduction in incidence across placebo-controlled PrEP trials. However, the quality of evidence for PrEP compares favorably with evidence for postexposure prophylaxis (PEP). It is clear from treatment programs and PrEP trials that daily adherence presents challenges to a large proportion of the population. Although there are factors associated with inconsistent use (ie, younger age), they do not assist clinicians at the point of care. There are additional provider concerns about PrEP (covering cost of drug and delivery, undermining condom promotion, and facilitating resistant strains) that have delayed widespread acceptance. These issues need to be addressed in order to realize the full public health potential of antiretrovirals. |
format | Online Article Text |
id | pubmed-4060254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40602542014-07-01 Biomedical Prevention: State of the Science McCormack, Sheena M. Gafos, Mitzy Desai, Monica Cohen, Myron S. Clin Infect Dis Controlling the HIV Epidemic with Antiretrovirals Preexposure prophylaxis (PrEP) and treatment as prevention (TasP) involve the use of antiretroviral (ARV) drugs by human immunodeficiency virus (HIV)-negative and -positive individuals to reduce HIV acquisition and transmission, respectively. Clinical science has delivered a consistently high effect size for TasP and a range from 0%–73% reduction in incidence across placebo-controlled PrEP trials. However, the quality of evidence for PrEP compares favorably with evidence for postexposure prophylaxis (PEP). It is clear from treatment programs and PrEP trials that daily adherence presents challenges to a large proportion of the population. Although there are factors associated with inconsistent use (ie, younger age), they do not assist clinicians at the point of care. There are additional provider concerns about PrEP (covering cost of drug and delivery, undermining condom promotion, and facilitating resistant strains) that have delayed widespread acceptance. These issues need to be addressed in order to realize the full public health potential of antiretrovirals. Oxford University Press 2014-07-01 /pmc/articles/PMC4060254/ /pubmed/24926033 http://dx.doi.org/10.1093/cid/ciu297 Text en © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Controlling the HIV Epidemic with Antiretrovirals McCormack, Sheena M. Gafos, Mitzy Desai, Monica Cohen, Myron S. Biomedical Prevention: State of the Science |
title | Biomedical Prevention: State of the Science |
title_full | Biomedical Prevention: State of the Science |
title_fullStr | Biomedical Prevention: State of the Science |
title_full_unstemmed | Biomedical Prevention: State of the Science |
title_short | Biomedical Prevention: State of the Science |
title_sort | biomedical prevention: state of the science |
topic | Controlling the HIV Epidemic with Antiretrovirals |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060254/ https://www.ncbi.nlm.nih.gov/pubmed/24926033 http://dx.doi.org/10.1093/cid/ciu297 |
work_keys_str_mv | AT mccormacksheenam biomedicalpreventionstateofthescience AT gafosmitzy biomedicalpreventionstateofthescience AT desaimonica biomedicalpreventionstateofthescience AT cohenmyrons biomedicalpreventionstateofthescience |